Profiles for companies starting with 'n'
✉ Email this page to a colleague
Drugs and US Patents for n
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TAFINLAR | dabrafenib mesylate | TABLET, FOR SUSPENSION;ORAL | 217514-001 | Mar 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-001 | Dec 4, 2015 | RX | Yes | No | 10,857,143 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-001 | Apr 5, 2022 | RX | Yes | No | 12,427,141 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | SERPASIL | reserpine | TABLET;ORAL | 009115-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
